Fig. 1From: Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United StatesOS (top panel) and PFS (bottom panel) Kaplan–Meier curves with best-fitting parametric curves. KM, Kaplan–Meier; OS, overall survival; PFS, progression-free survivalBack to article page